These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 564247)
1. Measurement of whole body calcium in chronic renal failure: effects of 1alpha-hydroxyvitamin D3 and parathyroidectomy. Naik RB; Dabek JT; Heynen G; James HM; Kanis JA; Robertson PW; Robinson BH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():139s-145s. PubMed ID: 564247 [TBL] [Abstract][Full Text] [Related]
2. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422 [TBL] [Abstract][Full Text] [Related]
3. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820 [TBL] [Abstract][Full Text] [Related]
4. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy. Junor BJ; Catto GR Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411 [TBL] [Abstract][Full Text] [Related]
5. Bone histomorphometry in patients with chronic renal failure: effect of 1alpha-hydroxyvitamin D3. Melsen F; Nielsen HE; Christensen MS Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():39s-44s. PubMed ID: 606423 [TBL] [Abstract][Full Text] [Related]
6. The effect of dialysate calcium concentration on 1alpha-hydroxyvitamin D3 on skeletal calcium loss and hyperparathyroidism in haemodialysis patients. Winney RJ; Tothill P; Robson JS; Abbot SR; Lidgard GP; Cameron EH; Smith MA; Macpherson HN; Strong JA Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():151s-158s. PubMed ID: 606413 [TBL] [Abstract][Full Text] [Related]
7. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure. Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427 [TBL] [Abstract][Full Text] [Related]
9. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy. Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125 [TBL] [Abstract][Full Text] [Related]
10. Factors influencing the response to 1alpha-hydroxyvitamin D3 in patients with renal bone disease. Kanis JA; Russell RG; Naik RB; Earnshaw M; Smith R; Heynen G; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():51s-57s. PubMed ID: 606425 [TBL] [Abstract][Full Text] [Related]
11. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409 [TBL] [Abstract][Full Text] [Related]
12. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3. Peacock M; Aaron JE; Walker GS; Davison AM Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428 [No Abstract] [Full Text] [Related]
14. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis. Ellis HA; Peart KM J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806 [TBL] [Abstract][Full Text] [Related]
15. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency. Pietrek J; Kokot F; Kuska J Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946 [TBL] [Abstract][Full Text] [Related]
16. The investigation and treatment of renal bone disease. Catto GR; MacLeod M Am J Med; 1976 Jul; 61(1):64-73. PubMed ID: 937372 [TBL] [Abstract][Full Text] [Related]
17. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease. Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424 [TBL] [Abstract][Full Text] [Related]
18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
19. An evaluation of 1 alpha-hydroxy-and 1,25-dihydroxyvitamin D3 in the treatment of renal bone disease. Kanis JA; Russell RG; Cundy T; Earnshaw M; Woods CG; Smith R; Heynen G Contrib Nephrol; 1980; 18():12-28. PubMed ID: 7353370 [TBL] [Abstract][Full Text] [Related]
20. The effects of calciferol and its metabolites on patients with chronic renal failure. II. Calcitriol, 1 alpha-hydroxyvitamin D3, and 24,25-dihydroxyvitamin D3. Voigts AL; Felsenfeld AJ; Llach F Arch Intern Med; 1983 Jun; 143(6):1205-11. PubMed ID: 6344827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]